Shares of Hims & Hers Health faced significant selling pressure on Friday after Bank of America Securities released a critical research report that questioned the company's growth trajectory. The analysis sent the telehealth pioneer's stock tumbling, casting doubt on its recent impressive performance. Bank of America Securities not only reaffirmed its "Underperform" rating but presented concerning data that rattled investors. According to their findings, order volumes during September plummeted by 16% compared to the same period last year. The financial institution subsequently slashed its fourth-quarter revenue projection to $590 million, substantially below the market consensus of $632 million. This development has introduced uncertainty around the company's explosive growth narrative, which had previously driven share appreciation exceeding 100% year-to-date. Market observers note... Read more...